Skip to main content
S&P 5007,557.11+0.21%DOW51,662.44-0.62%NASDAQ25,321.78+0.63%BTC$77,269.00-0.65%ETH$2,284.10-0.07%GOLD$3,954.80-0.37%OIL$95.85-0.63%
Smart Investors Daily
SID Premium
ME

NASDAQ · MESO

Mesoblast Limited

Healthcare · Biotechnology

$14.54

Up+$0.48 (+3.31%)

Updated Nov 3, 2026, 3:07 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.36B
P/E ratio
-27.76
Dividend yield
0.00%
52-week range
$11.89 – $21.50
Volume
261.72K
Avg. volume
231.33K

Price performance · MESO

MESO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

MESO closed at $14.54 after 21 trading sessions, up 2.25% for the selected period.

Last close
$14.54
Period change
+2.25%
Period low
$11.95
Period high
$15.67
Daily close
View OHLC price history
MESO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$15.08$15.08$14.51$14.54261.72K
Oct 30, 2026$15.38$15.69$14.84$15.16375.99K
Oct 29, 2026$15.50$15.82$15.30$15.67698.52K
Oct 28, 2026$13.24$13.39$13.12$13.39174.38K
Oct 27, 2026$12.95$13.20$12.88$13.18215.6K
Oct 26, 2026$12.38$12.48$12.33$12.39107.35K
Oct 23, 2026$12.38$12.38$12.21$12.28102.69K
Oct 22, 2026$12.80$12.93$12.49$12.55236.78K
Oct 21, 2026$12.98$13.115$12.78$12.83555.44K
Oct 20, 2026$11.95$12.51$11.95$12.41245.57K
Oct 19, 2026$12.48$12.50$11.89$11.95617.86K
Oct 16, 2026$13.91$13.91$12.938$13.28615.69K
Oct 15, 2026$13.56$14.00$13.50$13.95290.03K
Oct 14, 2026$13.75$13.95$13.68$13.79225.65K
Oct 13, 2026$14.26$14.26$13.895$13.895260.46K
Oct 12, 2026$14.47$14.47$14.27$14.27143.76K
Oct 9, 2026$13.93$14.38$13.93$14.29178.17K
Oct 8, 2026$13.62$13.76$13.41$13.75239.28K
Oct 7, 2026$13.71$14.10$13.71$13.94242.13K
Oct 6, 2026$13.90$13.90$13.575$13.61404.7K
Oct 5, 2026$14.09$14.30$13.97$14.22181.08K

Latest MESO news

The latest Smart Investors Daily articles mentioning MESO.

Stock researchCompany · Overview

MESO research

Overview

Company profile and research snapshot.

Company profile

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$11.50
Implied upside
—
Analysts
—
MESO recent ratings
DateFirmRatingTarget
Sep 22, 2026BELL POTTER SECURITIESBuy—
Sep 5, 2026CANACCORD GENUITYBuy—
Sep 3, 2026MAXIM GROUPBuy—
Sep 2, 2026JEFFERIESBuy—
Aug 28, 2026CANTOR FITZGERALDOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Emerald Resources And 2 Australian Growth Stocks To Watch

Global markets have been shaken by a broad sell off in artificial intelligence stocks as investors question high costs and scarce capital. That kind of reset can punish hype and reward actual progress. Australian high growth opportunities with strong conviction from both analysts and management sit right in that sweet spot. This article walks through three such stocks that fit this high conviction growth profile and explains why they may warrant a closer look. The three companies covered...

Yahoo · Oct 22, 2026

3 Australian Founder Led Stocks With Revenue Up To A$2.9b

Oil prices recently moved above $111 a barrel after attacks on Saudi energy facilities, sharpening the focus on resilient leadership in unpredictable markets. When costs and supply chains can shift overnight, founders with substantial personal reputations tied to their companies often show a different level of commitment. This article highlights three Australian founder-led stocks from our screener that embody that mindset and are worth a closer look. The three stocks highlighted here offer a...

Yahoo · Oct 22, 2026

Cochlear Heads These 3 Top Australian Healthcare Stocks To Watch

Oil prices have pushed above $110 a barrel as conflict in the Middle East disrupts supply routes and keeps energy costs high. That kind of pressure on household and government budgets often makes resilient Australian healthcare stocks look more attractive to long term investors seeking steadier demand. This article highlights three companies from a high quality healthcare shortlist that may help anchor a diversified portfolio when headlines turn volatile. The three healthcare stocks in this...

Yahoo · Oct 19, 2026

3 Australian Growth Stocks To Own In October 2026

China’s recent 4.5% GDP result, powered by strong high tech exports, shows how quickly capital can flow toward companies that capture a clear growth story. Australian high growth businesses with management heavily invested in their own shares tap into a similar idea. You get leadership that feels every win and mistake alongside you. This article highlights three such fast growing, owner backed stocks from our screener. The three stocks highlighted here offer a compelling starting point if you...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By